FDA posts briefing materials prior to Advisory Committee meeting for nonacog beta pegol, a long-acting factor IX for the treatment of haemophilia B

Bagsværd, Denmark, 31 March 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the Advisory Committee meeting to discuss the Biologics License Application for nonacog beta pegol, a long-acting factor IX for the treatment of haemophilia B. The meeting takes place on 4 April 2017. The briefing documents from Novo Nordisk and the FDA, which will form the basis for the Advisory Committee's discussion, provide an overview of the non-clinical and clinical data for nonacog beta pegol for the treatment of haemophilia B. The briefing materials can be accessed on the FDA webpage Further information Media: Katrine Sperling +45 4442 6718 [email protected] Courtney Mallon (US) +1 609 786 4079 [email protected] Ken Inchausti (US) +1 609 786 8316 [email protected] Investors: Peter Hugreffe Ankersen +45 3075 9085 [email protected] Hanna Ögren +45 3079 8519 [email protected] Anders Mikkelsen +45 3079 4461 [email protected] Kasper Veje (US) +1 609 235 8567 [email protected] Company announcement No 25 / 2017

The release as fetched from its publisher. novonordisk.com ↗